Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89
| Autor: | Carlo Ludovico Maini, M Broccatelli, Rosa Sciuto, Tofani A, C Fiumara, M.G. Scelsa |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Radiation-Sensitizing Agents Radiosensitizer medicine.medical_specialty medicine.medical_treatment Urology Pain Bone Neoplasms Breast Neoplasms Carboplatin Metastasis chemistry.chemical_compound medicine Humans Combined Modality Therapy Radiology Nuclear Medicine and imaging Adverse effect Aged business.industry Palliative Care Prostatic Neoplasms General Medicine Middle Aged medicine.disease Surgery Clinical trial Radiation therapy Radioisotope therapy chemistry Strontium Radioisotopes Female business |
| Zdroj: | Nuclear Medicine Communications. 17:799-804 |
| ISSN: | 0143-3636 |
| DOI: | 10.1097/00006231-199609000-00011 |
| Popis: | Strontium-89 (89Sr) is currently used for the treatment of painful bone metastases. This study reports the use of low-dose carboplatin as a radiosensitizer in 89Sr radioisotope therapy. The study design comprised two groups: 15 patients treated with 89Sr (148 MBq) followed by carboplatin (100 mg m-2 at 7 and 21 days) and 15 patients treated with 89Sr alone. Their pain response was assessed 8 weeks post-injection. Follow-up was continued for up to 1 year in the survivors. Twenty-seven patients were evaluable. A pain response was observed in 20 of 27 (74%) patients. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). No clinically significant adverse effects or myelosuppression by carboplatin were observed. Low-dose carboplatin enhances the effects of 89Sr radioisotope therapy on pain from bone metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|